CDK8-IN-19
CDK8-IN-19 (Compound 3d) is a CDK8 inhibitor with an IC50 of 25.08 nM. CDK8-IN-19 has a broad-spectrum anticancer activity, such as leukemia, melanoma and breast cancer, without significant cytotoxic effect on the normal Vero cells (mean IC50s of 2.87, 3.65, 3.79 and 45.48 μM, respectively) [1].
Product Specifications
UNSPSC
12352005
Target
CDK; PI3K
Related Pathways
Cell Cycle/DNA Damage; PI3K/Akt/mTOR
Field of Research
Cancer
Smiles
S=C(NC1=CC=C(Cl)C=C1Cl)NC(S/C2=C/C3=CC=CC=C3)=NC2=O
Molecular Formula
C17H11Cl2N3OS2
Molecular Weight
408.32
References & Citations
[1]Mohamed AR, et al. Integrated structure- and ligand-based design, synthesis, and biological evaluation of potent thiazole-based multi-kinase PI3Kα and CDK2/8 inhibitors as anticancer agents. Eur J Med Chem. 2025 Oct 15;296:117902.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK2; CDK8; PI3Kα
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
IRTTGFB1KT 1 Each
Rat Transforming Growth Factor Beta 1 (TGFb1) ELISA Kit
Sign In for Pricing
View Details 434762-01 1 mg
5-[4-Bromo-1-methyl-5- (trifluoromethyl) -1H-pyrazol-3-yl]-2-chloro-4-fluorobenzoic Acid-d3
Sign In for Pricing
View Details 434762-02 5 mg
5-[4-Bromo-1-methyl-5- (trifluoromethyl) -1H-pyrazol-3-yl]-2-chloro-4-fluorobenzoic Acid-d3
Sign In for Pricing
View Details